Enanta Pharmaceuticals (ENTA) Non-Current Assets (2012 - 2026)
Enanta Pharmaceuticals' (ENTA) quarterly Non-Current Assets came in at $136.3 million in Q1 2026, up 70.08% YoY from $80.1 million in Q1 2025, and up 4.18% on a QoQ basis from $130.8 million in Q4 2025.
Enanta Pharmaceuticals (ENTA) Non-Current Assets (2012 - 2026) Analysis & Trends
Enanta Pharmaceuticals (ENTA) has 15 years of Non-Current Assets data on file, last reported at $136.3 million in Q1 2026.
- Quarterly Non-Current Assets rose 70.08% year-over-year to $136.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $421.8 million (up 20.64% YoY) and the FY2025 annual result came in at $76.4 million, down 0.53% from the prior year.
- Non-Current Assets improved to $136.3 million in Q1 2026, from $130.8 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $136.3 million in Q1 2026 to a low of $38.2 million in Q4 2023.
- A 5-year average of $75.2 million and a median of $72.2 million in 2022 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2022 — Non-Current Assets sank 46.82% — and 2024, when it surged 140.32%.
- Tracing ENTA's Non-Current Assets over 5 years: stood at $63.8 million in 2022, then sank by 40.16% to $38.2 million in 2023, then soared by 110.75% to $80.5 million in 2024, then surged by 62.51% to $130.8 million in 2025, then grew by 4.18% to $136.3 million in 2026.
- The last three Non-Current Assets figures came in at $136.3 million (Q1 2026), $130.8 million (Q4 2025), and $76.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Enanta Pharmaceuticals | 383.29 Mn | 193.78 Mn | - | 93.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 93.25 Mn |
| Mar 31, 2026 | 136.29 Mn |
| Dec 31, 2025 | 130.82 Mn |
| Sep 30, 2025 | 76.40 Mn |
| Jun 30, 2025 | 78.32 Mn |
| Mar 31, 2025 | 80.13 Mn |
| Dec 31, 2024 | 80.50 Mn |
| Sep 30, 2024 | 76.80 Mn |
| Jun 30, 2024 | 112.24 Mn |
| Mar 31, 2024 | 62.53 Mn |
| Dec 31, 2023 | 38.20 Mn |
| Sep 30, 2023 | 39.48 Mn |
| Jun 30, 2023 | 46.70 Mn |
| Mar 31, 2023 | 55.31 Mn |
| Dec 31, 2022 | 63.83 Mn |
| Sep 30, 2022 | 63.70 Mn |
| Jun 30, 2022 | 72.18 Mn |
| Mar 31, 2022 | 64.95 Mn |
| Dec 31, 2021 | 113.64 Mn |
| Sep 30, 2021 | 119.77 Mn |